We’ve known it for A LONG TIME and we’ve mentioned it several times before – Big Pharma does not have patients’ best interests in mind — and heart. All they care about is generating revenues for their healthcare business.
Does it sound as if we have an ax to grind against Big Pharma? Of course I do! 9 Pharmaceutical companies teamed up with 5 medical societies to have my clinic illegally closed by the Philippines FDA who has no jurisdiction over medical clinics. But, pesky legal issues like due process and jurisdiction can’t stop the wheels of progress when Big Pharma collaborates with their government stooges to shut down a successful competitor.
The Big Reveal
Social media is all agog over the latest fiasco featured in the major news agencies. Reported by the news website CNBC, they quoted a recent Goldman Sachs biotech industry report asking the taboo question: “Is curing patients a sustainable business model?”
This question was incorporated in the company’s report called “The Genome Revolution” which elaborates on new gene therapy treatments and the outlook for the biotech industry. The new treatment is reported to potentially heal or cure multiple diseases if all goes well according to the plan. But skepticism greeted this report following another report (retracted now) of these gene therapies causing “hundreds of unintentional mutations” in the targeted organism
And the inevitable question popped out in the report, wherein the analyst asked if this new gene therapy will be consistently profitable to the big pharma companies – or will it harm their humungous profits? The following is the exact quote from Goldman Sach’s analyst Salveen Richter who wrote the report:
“The potential to deliver ‘one shot cures’ is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies.
Richter further commented, “While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.”
Are “we the consumers, the patients” just going to be looked on as sources of “sustained cash flow”? When will Big Pharma realize that they are toying with the lives of patients and society, particularly with cancer patients whose lives are on the balance with the conventional treatments (chemo, surgery, and radiation) that they thrust on us while we generate the needed, continuous “cash flow” that these big companies keep harping about.
What happened to the Hippocratic Oath that Big Pharma is supposed to adhere to upholding the health and safety of their patients, and not focus primarily on the revenue side of the profession?
Richter further cited a treatment for Hepatitis C offered by biotech company Gilead Sciences, which achieved cure rates of more than 90%. The analyst said that although hepatitis C treatments peaked at US$12.5 billion in 2015, its profits have been falling since then to just US$4 billion this year.
She further analyzes the company’s future by questioning whether the hepatitis C franchise has “gradually exhausted the available pool of treatable patients”. She quotes: “In the case of infectious diseases such as hepatitis C, curing existing patients also decreases the number of carriers able to transmit the virus to new patients, thus the incident pool also declines … Where an incident pool remains stable (e.g., in cancer) the potential for a cure poses less risk to the sustainability of a franchise.”
So Cancer is the perfect disease to invest their research & development dollars in because the “incident pool remains stable” compared to other diseases. And that is the reason why we at the Dr. Farrah Agustin-Bunch Natural Medical Center have always asserted that conventional medicine and big pharma companies will NEVER EVER be able to come out with a cure for cancer. It is not “profitable” to them.
What do you think of the biotech report from Goldman Sachs? Do you agree that Big Pharma should treat their consumers and patients like an unending source of revenues? Share your opinions in the comments below.